Zydus Cadila, an Indian pharmaceutical company, has obtained final approval from the US Food and Drug Administration (FDA) to market Clindamycin Phosphate and Benzoyl Peroxide Gel.
The dug will be produced at the group’s Topical manufacturing facility at Ahmedabad in Gujarat, India.
This combination medication, according to the pharma company, is used to treat a certain type of acne (inflammatory acne vulgaris).
The medicine is said to be effecting in reducing the number of acne pimples.
Clindamycin, an antibiotic, prevents the growth of acne-causing bacteria. Benzoyl peroxide is also found to be effective in thwarting the growth of bacteria besides decreasing the oil production in the skin.
Currently, the group has 242 approvals and has so far filed more than 340 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila discovers, develops, manufactures and markets an assortment of healthcare therapies. It has a work force of more than 23,000 employees across the globe.
Dedicated to creating healthier communities globally, Zydus seeks to emerge as a research-based pharmaceutical company by 2020.